title: The effects of endoxifen and other major metabolites of tamoxifen on the sulfation of estradiol catalyzed by human cytosolic sulfotransferases hSULT1E1 and hSULT1A1*1.
abstract: Tamoxifen is successfully used for both treatment and prevention of estrogen-dependent breast cancer, yet side effects and development of resistance remain problematic. Endoxifen is a major active metabolite of tamoxifen that is being investigated for clinical use. We hypothesized that endoxifen and perhaps other major metabolites of tamoxifen may affect the ability of human estrogen sulfotransferase 1E1 (hSULT1E1) and human phenol sulfotransferase 1A1 isoform 1 (hSULT1A1*1) to catalyze the sulfation of estradiol, an important mechanism in termination of estrogen signaling through loss of activity at estrogen receptors. Our results indicated that endoxifen, N-desmethyltamoxifen (N-desTAM), 4-hydroxytamoxifen (4-OHTAM), and tamoxifen-N-oxide were weak inhibitors of hSULT1E1 with Ki values ranging from 10 μM to 38 μM (i.e., over 1000 times higher than the 8.1 nM Km value for estradiol as substrate for the enzyme). In contrast to the results with hSULT1E1, endoxifen and 4-OHTAM were significant inhibitors of the sulfation of 2.0 µM estradiol catalyzed by hSULT1A1*1, with IC50 values (9.9 μM and 1.6 μM, respectively) that were similar to the Km value (1.5 μM) for estradiol as substrate for this enzyme. Additional investigation of the interaction of these metabolites with the two sulfotransferases revealed that endoxifen, 4-OHTAM, and N-desTAM were substrates for hSULT1E1 and hSULT1A1*1, although the relative catalytic efficiencies varied with both the substrate and the enzyme. These results may assist in future elucidation of cell- and tissue-specific effects of tamoxifen and its metabolites.
authors.affiliation: Department of Pharmaceutical Sciences and Experimental Therapeutics, Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa.
authors.forename: Edwin J
authors.initials: EJ
authors.lastname: Squirewell
authors.affiliation: Department of Pharmaceutical Sciences and Experimental Therapeutics, Division of Medicinal and Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City, Iowa michael-duffel@uiowa.edu.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Duffel
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000378:metabolism / Q000494:pharmacology*; D015239:Arylsulfotransferase / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D004958:Estradiol / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013379:Substrate Specificity; D015238:Sulfotransferases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D011994:Recombinant Proteins; D013629:Tamoxifen; C016601:afimoxifene; C055492:4-hydroxy-N-desmethyltamoxifen; D004958:Estradiol; C035830:tamoxifen N-oxide; D015238:Sulfotransferases; D015239:Arylsulfotransferase; C117544:SULT1A1 protein, human; C020122:estrone sulfotransferase; C028787:N-desmethyltamoxifen
references.citation: Methods Enzymol. 1981;77:206-13
references.pmid: 6173569
references.citation: Breast Cancer Res. 2005;7(3):R284-90
references.pmid: 15987423
references.citation: Pharmacol Rev. 1998 Jun;50(2):151-96
references.pmid: 9647865
references.citation: Mol Cell Endocrinol. 1982 Aug;27(3):291-306
references.pmid: 7128917
references.citation: Pharmacogenomics J. 2011 Apr;11(2):100-7
references.pmid: 20309015
references.citation: J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40
references.pmid: 12419790
references.citation: Steroids. 2007 Nov;72(13):829-42
references.pmid: 17765940
references.citation: Biochem Biophys Res Commun. 1994 May 16;200(3):1621-9
references.pmid: 8185618
references.citation: Cancer Res. 1991 Nov 15;51(22):6052-8
references.pmid: 1933868
references.citation: Cancer Res. 2003 Jun 1;63(11):2762-70
references.pmid: 12782580
references.citation: Drug Metab Dispos. 2006 Mar;34(3):361-8
references.pmid: 16381672
references.citation: Chem Biol Interact. 1998 Feb 20;109(1-3):329-39
references.pmid: 9566756
references.citation: Cancer Res. 2009 Mar 1;69(5):1722-7
references.pmid: 19244106
references.citation: Carcinogenesis. 2014 May;35(5):1172-6
references.pmid: 24501327
references.citation: Mol Hum Reprod. 1999 Nov;5(11):995-1002
references.pmid: 10541560
references.citation: Mol Pharmacol. 2006 Jun;69(6):2084-92
references.pmid: 16517757
references.citation: Breast Cancer Res Treat. 2006 Jan;95(1):13-6
references.pmid: 16317586
references.citation: Clin Chem. 2009 Oct;55(10):1770-82
references.pmid: 19574470
references.citation: J Clin Endocrinol Metab. 2002 Dec;87(12):5760-8
references.pmid: 12466383
references.citation: J Endocrinol. 1977 Nov;75(2):305-16
references.pmid: 591813
references.citation: Lancet. 1994 Feb 19;343(8895):448-52
references.pmid: 7905955
references.citation: Biochem Pharmacol. 1999 Aug 15;58(4):605-16
references.pmid: 10413297
references.citation: FASEB J. 1997 Mar;11(4):206-16
references.pmid: 9068609
references.citation: Cancer Res. 1996 Apr 1;56(7):1551-5
references.pmid: 8603401
references.citation: Mol Cell Endocrinol. 2013 Dec 5;381(1-2):124-39
references.pmid: 23911898
references.citation: J Biol Chem. 1998 May 1;273(18):10888-92
references.pmid: 9556564
references.citation: J Natl Cancer Inst. 2003 Jun 4;95(11):779-90
references.pmid: 12783932
references.citation: Mol Pharmacol. 1993 Jan;43(1):70-7
references.pmid: 8423770
references.citation: Toxicology. 2008 Jul 10;249(1):85-90
references.pmid: 18502016
references.citation: Biochem Biophys Res Commun. 1997 Oct 9;239(1):298-304
references.pmid: 9345314
references.citation: J Steroid Biochem Mol Biol. 1995 Jun;52(6):529-39
references.pmid: 7779757
references.citation: J Natl Cancer Inst. 2014 Oct;106(10). pii: dju283. doi: 10.1093/jnci/dju283
references.pmid: 25258390
references.citation: Biochem J. 1990 Dec 15;272(3):597-604
references.pmid: 2268288
references.citation: Drug Metab Dispos. 2014 Nov;42(11):1843-50
references.pmid: 25157097
references.citation: Biochem Pharmacol. 1980 Jul 1;29(13):1977-9
references.pmid: 7397005
references.citation: N Engl J Med. 2001 Jan 25;344(4):276-85
references.pmid: 11172156
references.citation: Biochem J. 1999 Jan 1;337 ( Pt 1):45-9
references.pmid: 9854023
references.citation: Cancer Res. 1989 Dec 15;49(24 Pt 1):6929-34
references.pmid: 2582435
references.citation: Protein Expr Purif. 2001 Feb;21(1):235-42
references.pmid: 11162411
references.citation: J Natl Cancer Inst. 1999 Oct 6;91(19):1654-62
references.pmid: 10511593
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Breast Cancer Res. 2005;7(6):R909-21
references.pmid: 16280036
references.citation: Drug Metab Pharmacokinet. 2002;17(3):221-8
references.pmid: 15618673
references.citation: Drug Metab Dispos. 2010 Jan;38(1):200-7
references.pmid: 19812351
references.citation: Anal Biochem. 1989 Dec;183(2):320-4
references.pmid: 2624319
references.citation: Ann N Y Acad Sci. 2009 Feb;1155:88-98
references.pmid: 19250196
references.citation: Cancer Res. 1991 Sep 15;51(18):4837-44
references.pmid: 1893376
references.citation: Int J Mol Epidemiol Genet. 2010 Jan 30;1(2):92-103
references.pmid: 21537383